BN ImmunoTherapeutics Starts Clinical Trials With Prostate Cancer Vaccine

MOUNTAIN VIEW, California, June 4/PRNewswire-FirstCall/ -- BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies
with its therapeutic vaccine candidate against prostate cancer.

A Phase I/II safety and tolerability study in 18 male patients with
non-metastatic as well as hormone-insensitive prostate cancer has begun
enrolment in the US. Secondary objectives of the trial include examining the
ability of the vaccine to induce prostate antigen-specific immune responses,
as well as clinical anti-tumor activity. Preliminary data is expected during
second half year 2009.

The therapeutic vaccine, based on the company's MVA-BN(R) technology, is
designed to generate cellular and humoral immune responses to PSA and PAP
(prostate specific antigen and prostatic acid phosphatase), which are both
well-known prostate cancer tumor targets.

Prostate cancer is, along with breast cancer, in the top three cancer
market, each with more than 500,000 new diagnosed incidents globally per year
and only limited treatment options.

Reiner Laus, MD, President & CEO of BN ImmunoTherapeutics said: "The
initiation of clinical studies with our therapeutic prostate cancer vaccine
advances our cancer portfolio and with both breast and prostate cancer
vaccines in clinical development, we have now strengthened the cancer
business area, which is an essential part of our group strategy going
forward."

Located in Mountain View, California, BN ImmunoTherapeutics is a
subsidiary of Bavarian Nordic, headquartered in Denmark.

Bavarian Nordic A/S is a leading industrial biotechnology company
developing and producing novel vaccines for the treatment and prevention of
life-threatening diseases with a large unmet medical need. The company's
business strategy is focused in three areas: biodefence, cancer and
infectious diseases. Bavarian Nordic's proprietary and patented technology,
MVA-BN(R), has been demonstrated in clinical trials to be one of the world's
safest, multivalent vaccine vectors. Bavarian Nordic has ongoing contracts
with the US government for the late-stage development and procurement of the
company's third-generation smallpox vaccine, IMVAMUNE(R).

Bavarian Nordic is listed on the OMX Nordic Exchange Copenhagen under the
symbol BAVA.

For more information, please visit: http://www.bavarian-nordic.com

"Safe Harbour" Statement under the Private Securities Litigation Reform
Act of 1995:

Except for the historical information contained herein, this release
contains "forward-looking statements" within the meaning of the Private
Securities Reform Act of 1995. No "forward-looking statement" can be
guaranteed, and actual results may differ materially from those projected.
Bavarian Nordic undertakes no obligation to publicly update any
"forward-looking statement", whether as a result of new information, future
events, or otherwise. Additional information regarding risks and
uncertainties is set forth in the current Annual Report and in Bavarian
Nordic's periodic reports, if any, which we incorporate by reference.

Source: Bavarian Nordic A/S

Contact: Reiner Laus, President & CEO, BN ImmunoTherapeutics, Inc., +1-650-681-4660

2008-06-04 05:06:12 0376868 PRNEWSWIRE